Back to Search Start Over

DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence

Authors :
Jeff Saranchuk
Chiou-Miin Wang
Vickie Yao Wang
Tim H M Huang
Aaron M. Horning
Darrel Drachenberg
Zhao Lai
Sherry L. Abboud-Werner
Chun Liang Chen
Joseph Liu
Yi Chen
Ian M. Thompson
Robin J. Leach
Chun-Lin Lin
Tad Kroczak
Victor X. Jin
Anna D Louie
Sabine Mai
Javior Hernandez
Rohit R. Jadhav
Julius Adebayo Awe
Source :
The Prostate. 75:1790-1801
Publication Year :
2015
Publisher :
Wiley, 2015.

Abstract

BACKGROUND Altered DNA methylation in CpG islands of gene promoters has been implicated in prostate cancer (PCa) progression and can be used to predict disease outcome. In this study, we determine whether methylation changes of androgen biosynthesis pathway (ABP)-related genes in patients' plasma cell-free DNA (cfDNA) can serve as prognostic markers for biochemical recurrence (BCR). METHODS Methyl-binding domain capture sequencing (MBDCap-seq) was used to identify differentially methylated regions (DMRs) in primary tumors of patients who subsequently developed BCR or not, respectively. Methylation pyrosequencing of candidate loci was validated in cfDNA samples of 86 PCa patients taken at and/or post-radical prostatectomy (RP) using univariate and multivariate prediction analyses. RESULTS Putative DMRs in 13 of 30 ABP-related genes were found between tumors of BCR (n = 12) versus no evidence of disease (NED) (n = 15). In silico analysis of The Cancer Genome Atlas data confirmed increased DNA methylation of two loci—SRD5A2 and CYP11A1, which also correlated with their decreased expression, in tumors with subsequent BCR development. Their aberrant cfDNA methylation was also associated with detectable levels of PSA taken after patients' post-RP. Multivariate analysis of the change in cfDNA methylation at all of CpG sites measured along with patient's treatment history predicted if a patient will develop BCR with 77.5% overall accuracy. CONCLUSIONS Overall, increased DNA methylation of SRD5A2 and CYP11A1 related to androgen biosynthesis functions may play a role in BCR after patients' RP. The correlation between aberrant cfDNA methylation and detectable PSA in post-RP further suggests their utility as predictive markers for PCa recurrence. Prostate 75:1790–1801, 2015. © 2015 Wiley Periodicals, Inc.

Details

ISSN :
02704137
Volume :
75
Database :
OpenAIRE
Journal :
The Prostate
Accession number :
edsair.doi...........f633ca103162e6a845ad5910d3b26499